AMETEK (NYSE: AME) — 2026 Q2 Earnings Preview

Calendar note: AMETEK is scheduled to release results before the market opens today, Tuesday, August 4, 2026, followed by its conference call at 8:30 a.m. ET. The event is therefore today—not tomorrow. (ametekinc.gcs-web.com)

The setup

AMETEK enters the quarter with unusually strong operating momentum but also elevated expectations. First-quarter orders rose 23%, sales increased 11%, adjusted EPS grew 13%, core operating margin expanded 160 basis points, and free-cash-flow conversion was 107%. Management raised its full-year outlook and described demand as broad-based. (investors.ametek.com)

At the same time, AME finished August 3 near $244, equivalent to roughly 30x the midpoint of existing 2026 adjusted-EPS guidance. That valuation leaves less room for a merely in-line quarter: investors will probably want a clean beat, sustained order momentum and higher guidance. (investors.ametek.com)

Headline expectations

Metric	Q2 2026 expectation	Q2 2025 actual	Implied growth
Revenue	Approximately $1.95–$1.96B	$1.78B	About 10%
Adjusted EPS	$1.99 consensus	$1.78	About 12%
Company adjusted-EPS guidance	$1.96–$2.00	—	10%–12%
Company GAAP-EPS guidance	$1.73–$1.77	$1.55	—

Consensus is effectively at the upper end of management’s adjusted-EPS range, while the revenue estimate implies growth somewhat stronger than the company’s “high-single-digit” sales guidance. Consequently, simply reporting $1.99 may not qualify as a meaningful beat. (benzinga.com)

What matters most

1. Did Q1’s order surge convert into revenue?

The strongest argument for upside is the first quarter’s 23% order growth and record backlog. The key question is how much of that demand was scheduled for delivery in 2026 and how much remains longer-cycle backlog.

Investors should focus on:

• Total and organic order growth.
• Book-to-bill and backlog direction.
• Whether management still sees broad strength rather than a handful of large projects.
• Conversion of defense, power, nuclear, space and semiconductor orders into second-half sales.
• Any customer delays caused by trade, geopolitical or supply-chain uncertainty.

Orders do not need to repeat Q1’s 23% growth rate. But a sharp deceleration without a convincing explanation would weaken the case for above-plan second-half organic growth.

2. EIG needs to show that its inflection is real

Electronic Instruments Group was the main area where orders ran well ahead of current revenue in Q1. EIG sales increased 11%, but underlying growth was more modest than in EMG, while management emphasized strong demand across defense, power, process instrumentation and semiconductor applications. EIG core margin reached 31.4%, up 40 basis points. (investors.ametek.com)

A constructive Q2 would include:

• Faster organic sales growth as orders begin converting.
• Continued strength in process and power markets.
• Stable-to-higher core margins despite acquisition mix and growth investments.
• Evidence that semiconductor demand is broader than one or two large programs.

If EIG orders remain strong but revenue conversion is pushed further out, investors may accept it—provided backlog, customer schedules and second-half guidance remain intact.

3. Can EMG sustain exceptional profitability?

Electromechanical Group delivered the standout Q1 performance: sales rose 13%, operating income increased 33%, and reported margin reached 25.7%. On a core basis, management indicated margin expansion of roughly 410 basis points. (investors.ametek.com)

The comparison becomes more demanding as 2026 progresses. Investors should distinguish between:

• Sustainable productivity and pricing gains.
• Volume leverage that may moderate as comparisons become tougher.
• Mix benefits from aerospace, defense, medical and automation.
• Any normalization after an unusually strong Q1 margin result.

AMETEK previously expected approximately 35% full-year core incremental margins and about 50 basis points of full-year core margin expansion. Results comfortably above those assumptions would support another earnings-guidance increase. (tipranks.com)

4. Organic growth quality matters more than reported growth

First-quarter reported sales growth included meaningful acquisition and currency contributions. The report should therefore be evaluated on organic growth by segment and end market, not just the consolidated revenue number.

The most important end-market reads are:

• Aerospace and defense: Defense demand, commercial aerospace production and MRO activity.
• Process: Whether the project pipeline continues converting into orders and revenue.
• Power: Data centers, grid modernization, backup power, nuclear and simulation systems.
• Automation and engineered solutions: Whether strong demand remains broad-based.
• Medical: Continued performance at Paragon, balanced against tougher comparisons.
• Semiconductor: AI-related equipment demand and the durability of recent large wins.

A revenue beat driven mainly by acquisitions or currency, paired with soft organic orders, would be lower quality than a smaller headline beat accompanied by stronger organic growth and backlog.

Indicor is likely to dominate the call

Since AMETEK’s last earnings report, it agreed to acquire Indicor Instrumentation for approximately $5.0 billion in cash. Indicor generates roughly $1.1 billion of annual revenue, with approximately 50% aftermarket exposure. AMETEK described the price as roughly 14x EBITDA, expects leverage of approximately 2.3x at closing, targets annualized synergies equal to 10%–12% of sales, and expects first-year cash-EPS accretion. Closing remains targeted for the second half of 2026. (investors.ametek.com)

AMETEK subsequently expanded its revolver to $3.5 billion and established a $4.0 billion term-loan facility tied to the acquisition. (sec.gov)

Investors need updates on:

1. Regulatory approvals and closing timing.
2. Expected 2026 revenue and EPS contribution, based on the assumed closing date.
3. Interest expense and effective borrowing cost.
4. The pace of deleveraging after closing.
5. Synergy timing, especially how much of the 10%–12% target is achievable in years one, two and three.
6. Integration structure and management capacity given Indicor’s size.
7. Whether leverage temporarily limits additional acquisitions or share repurchases.

The strategic rationale appears consistent with AMETEK’s historical model, but Indicor is large enough that execution and financing now matter almost as much as the standalone quarter.

Other acquisition contribution

AMETEK completed its purchase of First Aviation Services on May 26. The business expands AMETEK’s defense-oriented aviation MRO and proprietary-components capabilities. Because it was owned for only part of Q2, its near-term contribution should be modest, but management may update its revenue contribution, integration progress and strategic fit with AMETEK’s existing MRO platform. (investors.ametek.com)

Full-year guidance: the likely stock-moving item

Existing 2026 guidance calls for:

• Overall sales growth in the high single digits.
• Organic sales growth in the mid-single digits.
• Adjusted EPS of $7.94–$8.14.
• GAAP EPS of $7.03–$7.23.
• Free-cash-flow conversion of approximately 110%–115% of net income. (investors.ametek.com)

AMETEK raised EPS guidance by $0.07 at the midpoint after Q1. With consensus already near the top of the Q2 range and the stock carrying a premium multiple, another modest raise may be necessary to produce a clearly positive reaction.

The most useful guidance disclosure would separate:

• The underlying or “standalone” AMETEK outlook.
• Contributions from completed smaller acquisitions.
• Any Indicor contribution based on an assumed closing date.
• Incremental interest and integration expenses.
• Acquisition-related amortization excluded from adjusted EPS.

What would constitute a good report?

Bullish outcome

• Adjusted EPS above $2.00.
• Revenue above approximately $1.96 billion, with solid organic growth.
• Orders remain comfortably positive despite the difficult Q1 comparison.
• EIG revenue begins catching up with orders.
• EMG retains most of its margin gains.
• Standalone full-year guidance is raised.
• Indicor remains on schedule, with financing and synergy assumptions reaffirmed.

In-line outcome

• Adjusted EPS of $1.98–$2.00.
• Revenue near $1.95–$1.97 billion.
• Orders normalize but remain healthy.
• Full-year guidance is maintained or raised only slightly.
• No change to Indicor timing.

This would be operationally respectable, but the share-price response could be muted given the valuation.

Bearish outcome

• Adjusted EPS below $1.96.
• Organic revenue or orders weaken materially.
• EIG’s expected recovery is delayed without a backlog offset.
• EMG margin expansion reverses more sharply than expected.
• Standalone guidance is unchanged despite a nominal beat, suggesting more second-half caution.
• Indicor closing is delayed, financing costs rise, or synergy expectations become less certain.

Bottom line

AMETEK’s fundamental setup is strong: record orders, broad exposure to attractive industrial markets, high margins, strong cash generation and a potentially meaningful new earnings engine in Indicor. The central issue is expectations.

For the stock to respond positively, AMETEK likely needs more than an adjusted-EPS result near $1.99. The higher-quality outcome would combine:

1. An earnings beat above the prior $2.00 ceiling.
2. Continued organic order and backlog strength.
3. Evidence that EIG’s order inflection is becoming revenue.
4. Durable EMG margins.
5. Higher standalone 2026 guidance.
6. A credible and increasingly detailed Indicor integration and deleveraging plan.

At approximately 30x the midpoint of current adjusted-EPS guidance, the report is less about whether AMETEK is performing well—it clearly has been—and more about whether earnings expectations can continue moving higher fast enough to support the valuation.